Novo Nordisk A/S (NVO) Trading Up 8.3% Following Dividend Announcement

Novo Nordisk A/S (NYSE:NVO) was up 8.3% during mid-day trading on Wednesday after the company announced a dividend. The company traded as high as $44.96 and last traded at $44.57, with a volume of 3,637,672 shares changing hands. The stock had previously closed at $41.15.

The newly announced dividend which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be given a dividend of $0.336 per share. This is an increase from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date is Friday, August 18th. This represents a yield of 1.07%. Novo Nordisk A/S’s dividend payout ratio is 35.84%.

Several research analysts recently issued reports on NVO shares. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, April 19th. TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. Finally, BidaskClub cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Five investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $53.00.

The firm has a 50 day moving average of $42.69 and a 200 day moving average of $38.73. The stock has a market capitalization of $113.51 billion, a PE ratio of 18.71 and a beta of 0.63.

Several hedge funds have recently made changes to their positions in the stock. Proficio Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the period. AlphaMark Advisors LLC increased its position in shares of Novo Nordisk A/S by 1.1% in the second quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after buying an additional 30 shares during the period. Parallel Advisors LLC increased its position in shares of Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the period. Finally, Advisory Services Network LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $127,000. 6.40% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2017/08/11/novo-nordisk-as-nvo-trading-up-8-3-following-dividend-announcement.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

What are top analysts saying about Novo Nordisk A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novo Nordisk A/S and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit